Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + Docetaxel in SMARCA4-deficient NSCLC (2nd line)
ChiCTR2500115144Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Dongguan People's Hospital. Primary endpoint: Objective Response Rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500115144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115144.